Herpesvirus reactivation during severe COVID-19 and high rate of immune defect - 02/11/21
, G. Moratelli a, E. Azoulay a, M. Darmon a, b
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | High rates of acquired infections have been reported in severe COVID-19 patients. |
• | We performed a competing risk analysis and used Fine and Gray model to assess time-dependent associations. |
• | We observed a high incidence of herpesvirus reactivation in ICU COVID-19 patients, rarely to significant levels. |
• | Hematological malignancy and organ transplantation were associated with viral reactivation. |
• | Viral reactivation was not associated with mortality and did not increase on steroids. |
Abstract |
Objective |
We assessed herpesvirus reactivation in severe SARS-CoV-2 infection.
Methods |
Retrospective study including consecutive patients admitted to an onco-hematology intensive care unit (ICU) for severe COVID-19. Replication of EBV, CMV, and HSV was evaluated. Competing risk analyses were used to assess the cumulative risk of viral reactivation, and time-dependent Cox and Fine and Gray models to assess risk factors for viral reactivation.
Results |
Among 100 patients, 38 were immunocompromised. Sixty-three patients presented viral reactivation (12% for HSV, 58% EBV and 19% CMV). Symptomatic patients received treatment. Overall cumulative incidence of viral reactivation was 56.1% [55.9–56.4] at 10 days. After adjustment, a preexisting hematological malignancy (sHR [95%CI]=0.31 [0.11–0.85]) and solid organ transplantation (sHR [95% CI]=2.09 [1.13–3.87]) remained independently associated with viral reactivation. Viral reactivation (P=0.34) was not associated with mortality.
Conclusions |
Incidence of herpesvirus reactivation in patients admitted to the ICU for severe COVID-19 was high, but rarely required antiviral treatment.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, SARS-CoV-2, Viral reactivation, CMV
Plan
Vol 51 - N° 8
P. 676-679 - novembre 2021 Retour au numéro
Article précédent
- Is the second dose of vaccination useful in previously SARS-CoV-2-infected healthcare workers?
- G. Pean De Ponfilly, B. Pilmis, I. El Kaibi, N. Castreau, S. Laplanche, A. Le Monnier
- An unusual digestive infection due to Francisella tularensis: A case report
- A. Zeggay, R. Anxionnat, C. Chirouze, P. Plésiat, K. Jeannot, Y. Caspar, A. Potron
Bienvenue sur EM-consulte, la référence des professionnels de santé.